The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Determinants of Outcome in Melanoma Patients With Cerebral Metastases
Abstract
Purpose: To analyze prognostic factors, effects of treatment, and survival for patients with cerebral metastases from melanoma. Patients and Methods: All melanoma patients with cerebral metastases treated at the Sydney Melanoma Unit between 1952 and 2000 were identified. From 1985 to 2000, patients were diagnosed and treated using consistent modern techniques and this cohort was analyzed in detail. Multivariate analysis of prognostic factors for survival was performed. Results: A total of 1,137 patients with cerebral metastases were identified; 686 were treated between 1985 and 2000. For these 686 patients, the median time from primary diagnosis to cerebral metastasis was 3.1 years (range, 0 to 41 years). A total of 646 patients (94%) have died as a result of melanoma. The median survival from the time of diagnosis of cerebral metastasis was 4.1 months (range, 0 to 17.2 years). Treatment was as follows: surgery and postoperative radiotherapy, 158 patients; surgery alone, 47 patients; radiotherapy alone, 236 patients; and supportive care alone, 210 patients. Median survival according to treatment received for these four groups was 8.9, 8.7, 3.4, and 2.1 months, respectively; the differences between surgery and nonsurgery groups were statistically significant. On multivariate analysis, significant factors associated with improved survival were surgical treatment (P < .0001), no concurrent extracerebral metastases (P < .0001), younger age (P = .0007), and longer disease-free interval (P = .036). Prognostic factors analysis confirmed the important influence of patient selection on treatment received. Conclusion: This large series documents the characteristics of patients who developed cerebral metastases from melanoma. Median survival was dependent on treatment, which in turn was dependent on patient selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Borgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., & Hendrickson, F. R. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90195-9 · Cited by 953
On distribution-free tests for equality of survival distributions
TARONE, R. E., & WARE, J. (1977) · Biometrika · doi:10.1093/biomet/64.1.156 · Cited by 729
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients
Lagerwaard, F., Levendag, P., Nowak, P. C. M., Eijkenboom, W. H., Hanssens, P. J., & Schmitz, P. M. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00442-8 · Cited by 721
Cited by
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 987
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Davies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Prognostic factors for survival in melanoma patients with brain metastases
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A. (2011) · Cancer · doi:10.1002/cncr.25634 · Cited by 548
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 390
Multidisciplinary Management of Brain Metastases
Eichler, A. F., & Loeffler, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-884 · Cited by 366
Brain metastases: epidemiology
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-811161-1.00002-5 · Cited by 336
Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17951-3 · Cited by 292
Self-citationDummer, R., Goldinger, S. M., Turtschi, C. P., Eggmann, N. B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R., Felderer, L., & Rinderknecht, J. D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.002 · Cited by 287
Ipilimumab and radiation therapy for melanoma brain metastases
Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013) · Cancer Medicine · doi:10.1002/cam4.140 · Cited by 280
Epidemiology of Brain Metastases
Sacks, P., & Rahman, M. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.001 · Cited by 279
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Davies, M. A., Stemke-Hale, K., Lin, E., Tellez, C., Deng, W., Gopal, Y. N., Woodman, S. E., Calderone, T. C., Ju, Z., Lazar, A. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1985 · Cited by 252
Metadata
- Authors
- Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., Milton, G. W., McCarthy, W. H., & Thompson, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-04-01
- Volume
- 22
- Issue
- 7
- Pages
- 1293-1300
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160379492
- Cited by
- 445
- References
- 21
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.